Overview With more than 5,000 people and sales of US$5.8 billion in 2014, Shire is one of the world’s fastest growing biotechnology compa- nies. It focuses on developing and delivering innovative medicines for patients with rare dis- eases and other specialty conditions. Challenge Shire shapes what’s next for people with rare diseases and specialty conditions. Through business development and R&D efforts focused on breakthrough science, we develop and de- liver best-in-class therapies for patients with rare and life-altering conditions. In 2015, we launched multiple products in our core thera- peutic areas, expanded our global footprint and strengthened our innovative pipeline, which is now the most robust in Shire’s 30-year history. We have nearly 30 programs in clinical devel

Join for free to read